Columbia University and Weill Cornell Medicine psychiatrists continue to investigate – in the clinic and in the lab – the potential role of ketamine in the treatment of resistant depression.

With more than a year of observing the wide-ranging impact of COVID-19 on multiple organ systems, psychiatrists have acquired a growing knowledge base of short- and long-term neuropsychiatric symptoms and long-term brain sequelae.

Scientists know that the prefrontal cortex is essential in both humans and animals for shifting attention in response to changing circumstances.

Researchers Kenneth Wengler, PhD and Guillermo Horga, MD, PhD have found evidence of a potential neurobiological mechanism for hallucinations and delusions that fit within the hierarchical model of psychosis and can explain their clinical presentation.

A study by investigators at Weill Cornell Medicine, NewYork-Presbyterian, and Yale University demonstrates that safety signals activate different circuits in the brain from those involved in typical anxiety therapy.

In May 2021, Vivian B. Pender, MD, Clinical Professor of Psychiatry at Weill Cornell Medicine and Lecturer in Psychoanalysis at Columbia University Vagelos College of Physicians and Surgeon, will assume the role as President of the American Psychiatric Association (APA).

In a quest to better define depression diagnosis, a neuroscientist and psychiatrist at NewYork-Presbyterian/Weill Cornell used fMRI brain scans to identify unique subtypes of depression.

Dr. Mann and his Columbia colleagues have been investigating the use of ketamine as a treatment option for rapidly reducing suicidal thoughts in patients with refractory depression.